SK283868B6 - Farmaceutický prostriedok so zvýšenou biodostupnosťou antihistaminika a použitie - Google Patents

Farmaceutický prostriedok so zvýšenou biodostupnosťou antihistaminika a použitie Download PDF

Info

Publication number
SK283868B6
SK283868B6 SK184-2000A SK1842000A SK283868B6 SK 283868 B6 SK283868 B6 SK 283868B6 SK 1842000 A SK1842000 A SK 1842000A SK 283868 B6 SK283868 B6 SK 283868B6
Authority
SK
Slovakia
Prior art keywords
peg
glycoprotein
inhibitor
fexofenadine
glycoprotein inhibitor
Prior art date
Application number
SK184-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK1842000A3 (en
Inventor
Kin-Kai Hwang
Dennis H. Giesing
Gail H. Hurst
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SK1842000A3 publication Critical patent/SK1842000A3/sk
Publication of SK283868B6 publication Critical patent/SK283868B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SK184-2000A 1997-08-14 1998-07-21 Farmaceutický prostriedok so zvýšenou biodostupnosťou antihistaminika a použitie SK283868B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14
PCT/US1998/015098 WO1999008690A1 (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Publications (2)

Publication Number Publication Date
SK1842000A3 SK1842000A3 (en) 2000-08-14
SK283868B6 true SK283868B6 (sk) 2004-03-02

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
SK184-2000A SK283868B6 (sk) 1997-08-14 1998-07-21 Farmaceutický prostriedok so zvýšenou biodostupnosťou antihistaminika a použitie

Country Status (29)

Country Link
EP (1) EP1003528B1 (enExample)
JP (1) JP4295913B2 (enExample)
KR (1) KR100522985B1 (enExample)
CN (1) CN1143680C (enExample)
AR (1) AR018505A1 (enExample)
AT (1) ATE224721T1 (enExample)
AU (1) AU725965C (enExample)
BR (1) BR9811937A (enExample)
CA (1) CA2301267C (enExample)
CZ (1) CZ293666B6 (enExample)
DE (1) DE69808303T2 (enExample)
DK (1) DK1003528T3 (enExample)
EE (1) EE04263B1 (enExample)
ES (1) ES2179523T3 (enExample)
HU (1) HU226823B1 (enExample)
ID (1) ID24463A (enExample)
IL (1) IL134521A (enExample)
NO (1) NO325148B1 (enExample)
NZ (1) NZ502133A (enExample)
OA (1) OA11287A (enExample)
PL (1) PL191607B1 (enExample)
PT (1) PT1003528E (enExample)
RU (1) RU2197967C2 (enExample)
SK (1) SK283868B6 (enExample)
TR (1) TR200000419T2 (enExample)
TW (1) TWI240633B (enExample)
UA (1) UA64765C2 (enExample)
WO (1) WO1999008690A1 (enExample)
ZA (1) ZA987221B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
WO2003101437A2 (en) * 2002-05-29 2003-12-11 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
EA201391742A1 (ru) 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
NO900427L (no) * 1989-01-31 1990-08-01 Int Pharma Agentur Erosjonsregulert frigjoeringssystem for aktive stoffer og en fremgangsmaate for deres fremstilling.
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
NO20000706L (no) 2000-04-13
CZ293666B6 (cs) 2004-06-16
EP1003528A1 (en) 2000-05-31
RU2197967C2 (ru) 2003-02-10
ZA987221B (en) 1999-02-15
DE69808303D1 (de) 2002-10-31
SK1842000A3 (en) 2000-08-14
HU226823B1 (hu) 2009-11-30
NZ502133A (en) 2002-03-28
IL134521A0 (en) 2001-04-30
UA64765C2 (uk) 2004-03-15
WO1999008690A1 (en) 1999-02-25
DK1003528T3 (da) 2003-02-03
PL191607B1 (pl) 2006-06-30
CN1267221A (zh) 2000-09-20
HK1025901A1 (en) 2000-12-01
EE200000069A (et) 2000-10-16
CA2301267A1 (en) 1999-02-25
PL338579A1 (en) 2000-11-06
JP4295913B2 (ja) 2009-07-15
ATE224721T1 (de) 2002-10-15
KR100522985B1 (ko) 2005-10-21
CN1143680C (zh) 2004-03-31
BR9811937A (pt) 2000-09-05
CZ2000522A3 (cs) 2000-09-13
DE69808303T2 (de) 2003-05-22
ID24463A (id) 2000-07-20
EP1003528B1 (en) 2002-09-25
AU725965B2 (en) 2000-10-26
OA11287A (en) 2003-10-22
NO20000706D0 (no) 2000-02-11
AU8505098A (en) 1999-03-08
AU725965C (en) 2004-04-22
TR200000419T2 (tr) 2000-09-21
HUP0003189A2 (en) 2001-03-28
EE04263B1 (et) 2004-04-15
KR20010022845A (ko) 2001-03-26
AR018505A1 (es) 2001-11-28
PT1003528E (pt) 2003-02-28
HUP0003189A3 (en) 2001-04-28
JP2001515041A (ja) 2001-09-18
CA2301267C (en) 2004-07-13
NO325148B1 (no) 2008-02-11
TWI240633B (en) 2005-10-01
ES2179523T3 (es) 2003-01-16
IL134521A (en) 2005-07-25

Similar Documents

Publication Publication Date Title
US6451815B1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
KR100522985B1 (ko) 펙소페나딘 및 그의 유도체의 생체내이용성 향상 방법
US6511985B1 (en) Combination of cerivastatin and fibrates
PL198357B1 (pl) Preparat farmaceutyczny do leczenia alergicznego i/lub naczynioruchowego nieżytu nosa lub alergicznego zapalenia spojówek, lek na bazie tego preparatu oraz sposób otrzymywania leku
CZ295090B6 (cs) Nová kombinace loteprednolu a antihistaminik
US20070286875A1 (en) Oral liquid loratadine formulations and methods
JPH01268633A (ja) Ｌ−ドーパの直腸被吸収性形態
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
JP2001515041A5 (enExample)
KR20010085503A (ko) 아지스로마이신의 생체이용성 및 조직 침투를 증가시키는방법
US6395720B1 (en) Synergistically acting compositions for selectively combating tumor tissue
US20260137672A1 (en) Sustained-release tablet comprising apixaban
SK282695B6 (sk) Použitie metoklopramidu
MXPA00001515A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
HK1025901B (en) Method of enhancing bioavailability of fexofenadine and its derivatives
AU2010338249B2 (en) Oral liquid pharmaceutical composition of nifedipine
US20060140985A1 (en) Lansoprazole formulations and related processes and methods
HK1132908A (en) Drug formulation containing fibrate medicament and process for producing the same
KR20070102953A (ko) 고지혈증의 예방 및/또는 치료를 위한 의약
EP2396001A1 (en) Par-1 antagonism in fed or antacid-dosed patients

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DELAWARE, US

Free format text: FORMER OWNER: HMR PHARMA, INC., GREENVILLE, DELAWARE, US

Effective date: 20011228

Owner name: HMR PHARMA, INC., GREENVILLE, DELAWARE, US

Free format text: FORMER OWNER: AVENTIS PHARMACEUTICALS INC., BRIDGEWATER, NJ, US

Effective date: 20011228

PC4A Assignment and transfer of rights

Owner name: AVENTISUB II INC., GREENVILLE, DELAWARE, US

Free format text: FORMER OWNER: AVENTIS HOLDINGS INC., GREENVILLE, DELAWARE, US

Effective date: 20100312

MK4A Expiry of patent

Expiry date: 20180721